Sanofi (ADR) (NYSE:SNY)

CAPS Rating: 5 out of 5

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.

Results 1 - 20 of 133 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar CityFrFTW (< 20) Submitted: 2/11/2014 2:21:02 AM : Outperform Start Price: $47.62 SNY Score: +4.41

My little finger

Recs

0
Member Avatar grahamfordummies (69.87) Submitted: 1/13/2014 3:49:30 PM : Outperform Start Price: $48.64 SNY Score: +2.92

Despite trading at a discount to the European Pharma group, growth will accelerate this year (beginning in this quarter) to well above the group. Less dependent on 'cliff pharma' and more diversified into 'longer duration assets' (e.g. biologics, vaccines, animal health, branded generics and OTC, etc.). Strategic deals have uniquely positioned SNY for longer term growth (e.g. Genzyme, Regeneron and now Alnylam).

Recs

0
Member Avatar MaliLuke (64.15) Submitted: 12/22/2013 5:27:47 AM : Outperform Start Price: $50.13 SNY Score: +0.08

A strong position in vaccines accross the globe with a good portfolio of drugs for diabetes, cardiovascular, oncology makes this a successful diversified healthcare of proper size as number 4 in prescriptions

Recs

0
Member Avatar line70day (< 20) Submitted: 12/10/2013 7:45:18 PM : Outperform Start Price: $49.58 SNY Score: +0.32

Devoloping Tasotere in treation non small-cell lung cancer .Peregrine hopes to serve as first step establishing its self as successful cancer -fighting agent.Is competition is catching up fast. Peregrin is using Bavituximab to treat cancer last monthreleased data showing that its antibodies produced tumor-fighting angents. Its sales of Celgene's Abrafane already has taken off.

Recs

0
Member Avatar wtcrane1 (95.55) Submitted: 8/7/2013 3:17:04 PM : Outperform Start Price: $51.23 SNY Score: -10.55

undervalued, wide moat

Recs

1
Member Avatar aeprescott89 (< 20) Submitted: 5/16/2013 4:33:10 PM : Outperform Start Price: $52.98 SNY Score: -16.40

Aging population (especially in Europe) will continue to increase dependency on prescription medications, also doing some great things with R&D.

Recs

1
Member Avatar eksummers620 (49.44) Submitted: 4/2/2013 12:06:15 AM : Outperform Start Price: $48.68 SNY Score: -14.46

BRK holding

Recs

1
Member Avatar robotclo (77.95) Submitted: 3/19/2013 2:13:10 AM : Outperform Start Price: $46.66 SNY Score: -10.72

Good year for health care...even in Europe

Recs

0
Member Avatar scrubs62074 (75.02) Submitted: 2/8/2013 3:47:47 PM : Outperform Start Price: $44.11 SNY Score: -7.00

High Volume Breakout on 02/08/13

Recs

0
Member Avatar TerryHoodSr (64.97) Submitted: 1/11/2013 3:45:21 PM : Outperform Start Price: $46.35 SNY Score: -16.99

EPS $6.90 TP $60

Recs

1
Member Avatar flynthewest (< 20) Submitted: 11/16/2012 11:40:26 AM : Outperform Start Price: $40.04 SNY Score: -10.01

Attach "Europe based" to nearly any company in this fall of 2012, and expect a measurable price discount. Add to that SNY's history of drug development and management coupled with the change growing population of drug consumers (read, more baby boomers aging), and you have a winner.

Recs

0
Member Avatar Fish08 (67.38) Submitted: 9/7/2012 1:51:40 PM : Outperform Start Price: $40.03 SNY Score: -1.32

Above average drug portfolio. Growth of existing and new products should more than make up for patent expirations.

Recs

0
Member Avatar cdb5556 (< 20) Submitted: 5/20/2012 5:12:35 PM : Underperform Start Price: $32.70 SNY Score: -14.26

no innovation, big patent cliff with Plavix/Lovenox/Lantus...nothing to replace them. Stock has done little over the past few years.

Recs

0
Member Avatar willerbeats (< 20) Submitted: 9/13/2011 2:43:48 PM : Outperform Start Price: $29.32 SNY Score: +17.20

India based biotech in under-represented market

Recs

0
Member Avatar GrizWin (< 20) Submitted: 9/6/2011 12:09:41 PM : Outperform Start Price: $31.28 SNY Score: +3.16

Dividend makes is "safer" in the short run but with pipeline and genzyme long term also looks good

Recs

0
Member Avatar Keekers44 (74.78) Submitted: 9/3/2011 12:09:41 PM : Outperform Start Price: $31.12 SNY Score: +1.86

This stock is a Cramer favorite with a decent 3.8% yeild. Cramer believes this company has a low valuation, and is an accidental high yeilder. Ken Fisher of Fisher Asset Management recently increased holdings to over 14,750,000 shares.

Recs

0
Member Avatar GarlicEater7 (< 20) Submitted: 8/10/2011 7:36:25 PM : Outperform Start Price: $28.19 SNY Score: +18.19

Strong pipeline and nice dividend make SNY a compelling buy at this price.

Recs

0
Member Avatar mtrade1 (< 20) Submitted: 6/15/2011 3:04:54 PM : Outperform Start Price: $33.11 SNY Score: +8.46

want 2 get it on the down turn. down 4% strong co.

Recs

0
Member Avatar FuriousGreen (96.43) Submitted: 5/2/2011 1:52:52 PM : Outperform Start Price: $35.10 SNY Score: +9.99

Caters to the baby boomer market, which will suddenly demand their products like a junky demands heroin.

Recs

0
Member Avatar RXDOC73 (99.34) Submitted: 2/6/2011 8:07:51 AM : Outperform Start Price: $30.00 SNY Score: +30.59

Growth and the money to back it!

Featured Broker Partners


Advertisement